Carregant...
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach
AIMS: Glycopyrronium bromide (NVA237) is a once-daily long-acting muscarinic antagonist recently approved for the treatment of chronic obstructive pulmonary disease. In this study, we used population pharmacokinetic (PK) modelling to provide insights into the impact of the lung PK of glycopyrronium...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Science Inc
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845310/ https://ncbi.nlm.nih.gov/pubmed/23506208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12118 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|